BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...

BioNTech (NASDAQ:BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.

BioNTech is taking a dual approach, developing personalized and off-the-shelf vaccines to address different cancer types. As BioNTech and Moderna push forward, the cancer treatment landscape could ...

BioNTech has announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the potential treatment of non-small cell lung cancer (NSCLC). The vaccine is claimed to use the ...

The oral and poster presentations will feature programs across BioNTech’s clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches.

2 variant. Lastly, BioNTech and DualityBio were granted Fast Track designation by the FDA for their investigational drug, BNT324/DB-1311, for treating metastatic castration-resistant prostate cancer.

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving ... AstraZeneca, Amgen, BioNTech, Eisai, GSK, ...

BioNTech (NASDAQ:BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from Hold, citing the potential of a new cancer drug it is developing with ...